Foralumab is a fully human anti-CD3 monoclonal antibody categorized as a novel immunomodulatory therapeutic agent. Developed distinctively for non-invasive mucosal administration via a nasal spray rather than traditional intravenous infusions, it is designed to bind to the CD3 epsilon subunit on T cells to stimulate regulatory T cells (Tregs). This targeted mechanism dampens unwanted neuroinflammation and immune system overactivation in autoimmune and neurodegenerative disorders—such as multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis—while successfully avoiding the severe systemic toxicities and broad immunosuppression associated with older antibody therapies.